Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    22821361 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Adult-to-Adult Living Donor Liver Transplantation Study
Conditions: Cirrhosis;   Hepatitis C;   Hepatocellular Carcinoma
Intervention:
2 Recruiting Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
Conditions: Hepatitis C Infection;   Viruses;   Hepatocellular Carcinoma;   Hepatitis, Viral, Human;   Liver Cirrhosis
Intervention: Biological: Civacir® 10%
3 Completed
Has Results
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
Condition: Hepatitis C
Intervention: Drug: LADR Treatment

Indicates status has not been verified in more than two years